TargetBeta
KLRC1
killer cell lectin like receptor C1 · also NKG2-A, NKG2-B, CD159a, NKG2 · CD molecules
2 programs in company-led studies act on KLRC1, from 2 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| monalizumab | AstraZeneca | phase 3 | 93 running | – | a judged reading |
| Anti-NKG2A/Anti-PD-L1 Bispecific Antibody XB628rule | Exelixis | phase 1 | 11 running | CD274 | NCIt |
Also acted on by the same programs
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 1 program
- Colonic Neoplasms, 1 program
- Head and Neck Neoplasms, 1 program
- Leukemia, Lymphocytic, Chronic, B-Cell, 1 program
- Neoplasm Metastasis, 1 program
- Squamous Cell Carcinoma of Head and Neck, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jan 8, 2027monalizumab · AstraZeneca · phase 3 · NCT05221840
- May 31, 2027Anti-NKG2A/Anti-PD-L1 Bispecific Antibody XB628 · Exelixis · phase 1 · NCT06952010
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.